Clinical Approach to Muscle Weakness

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of muscle weakness

Muscle weakness is one of the most common and diagnostically challenging complaints encountered in clinical practice, accounting for approximately 5% of all primary care visits and up to 10% of neurology consultations. The lifetime prevalence of significant muscle weakness is estimated at 10-15% of the general population. Weakness can range from mild functional impairment to life-threatening respiratory failure, making accurate localization and diagnosis essential. The diagnostic yield improves dramatically when clinicians systematically localize the lesion along the motor pathway before generating a differential diagnosis.

Definition

True weakness (paresis or plegia) refers to a reduction in the maximum force a muscle can generate, resulting from dysfunction anywhere along the motor pathway from the cerebral cortex to the muscle fiber itself. This must be distinguished from perceived weakness (asthenia or fatigue), where patients report feeling weak but demonstrate normal muscle strength on examination. True weakness implies pathology of the nervous system or muscle, while perceived weakness often reflects systemic illness, deconditioning, or psychiatric conditions.

Classification by Duration

Category	Duration	Common Causes	Clinical Significance
Acute	Hours to days (less than 4 weeks)	Stroke, Guillain-Barré syndrome, acute transverse myelitis, myasthenic crisis, periodic paralysis, rhabdomyolysis	Often represents neurological emergency; requires urgent evaluation for reversible causes
Subacute	Weeks to months (4 weeks to 6 months)	Inflammatory myopathies, subacute combined degeneration, paraneoplastic syndromes, chronic inflammatory demyelinating polyneuropathy	Suggests inflammatory, infectious, or neoplastic etiology; often treatable if identified early
Chronic	Greater than 6 months	Muscular dystrophies, motor neuron disease, hereditary neuropathies, inclusion body myositis, chronic denervation	Often progressive and degenerative; focus on establishing diagnosis, prognosis, and supportive care

Classification by Distribution Pattern

Proximal Weakness

Affected muscles: Shoulder girdle (deltoid, supraspinatus) and hip girdle (iliopsoas, glutei, quadriceps)

Functional impact: Difficulty rising from chairs, climbing stairs, reaching overhead, combing hair

Suggests: Myopathy (inflammatory, metabolic, toxic), neuromuscular junction disorders, some motor neuron diseases

Distal Weakness

Affected muscles: Intrinsic hand muscles, wrist extensors, ankle dorsiflexors, foot intrinsics

Functional impact: Difficulty with fine motor tasks, foot drop, tripping, hand grip weakness

Suggests: Peripheral neuropathy, distal myopathies, motor neuron disease (amyotrophic lateral sclerosis)

Symmetric Weakness

Pattern: Both sides of the body affected equally

Suggests: Myopathy, neuromuscular junction disorders, polyneuropathy, systemic causes

Asymmetric Weakness

Pattern: One side or specific muscle groups affected more than others

Suggests: Stroke, radiculopathy, mononeuropathy, motor neuron disease, focal central nervous system lesion

Classification by Motor Neuron Type

Feature	Upper Motor Neuron Weakness	Lower Motor Neuron Weakness
Lesion Location	Motor cortex, internal capsule, brainstem, spinal cord (above anterior horn)	Anterior horn cell, nerve root, peripheral nerve, neuromuscular junction, muscle
Distribution	Pyramidal pattern: arm extensors and leg flexors weaker	Follows specific nerve root, peripheral nerve, or muscle pattern
Muscle Tone	Increased (spasticity) — velocity-dependent	Decreased (flaccidity or hypotonia)
Deep Tendon Reflexes	Hyperreflexia, clonus	Hyporeflexia or areflexia
Pathological Reflexes	Babinski sign positive (extensor plantar response)	Babinski sign negative (flexor plantar response)
Muscle Bulk	Preserved initially; late mild atrophy from disuse	Early and prominent atrophy
Fasciculations	Absent	Present (especially in anterior horn cell disease)

Classification by Temporal Pattern

Pattern	Description	Suggests
Sudden onset (seconds to minutes)	Weakness develops abruptly, often with maximal deficit at onset	Vascular event (stroke, spinal cord infarction), trauma
Rapid progressive (hours to days)	Weakness worsens over short period, may ascend	Guillain-Barré syndrome, acute transverse myelitis, myasthenic crisis
Fluctuating	Weakness varies throughout the day or with activity	Myasthenia gravis (worse with use, better with rest), periodic paralysis
Episodic	Discrete attacks of weakness with normal intervals	Periodic paralysis, transient ischemic attack, multiple sclerosis relapse
Progressive (months to years)	Gradual worsening without remission	Motor neuron disease, muscular dystrophy, chronic neuropathy, inclusion body myositis
Static or slowly progressive	Weakness present from birth or early life, minimal change	Congenital myopathies, cerebral palsy, hereditary conditions

Key Concept: The Localization Principle

The foundation of evaluating muscle weakness is anatomical localization along the motor pathway. Before generating a differential diagnosis, clinicians must determine where the lesion is located:

Central nervous system: Brain (cortex, internal capsule, brainstem) or spinal cord
Anterior horn cell: Motor neuron cell bodies in the spinal cord
Peripheral nerve: Nerve roots, plexus, or peripheral nerves
Neuromuscular junction: The synapse between nerve and muscle
Muscle: The muscle fiber itself (myopathy)

Each location produces a characteristic pattern of weakness, reflexes, sensory findings, and associated features that guide the diagnostic workup.

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of muscle weakness

Understanding the motor pathway from cortex to muscle is essential for localizing weakness. Voluntary movement requires intact function at every level: the upper motor neuron (from cortex to spinal cord), the lower motor neuron (from spinal cord to muscle), the neuromuscular junction, and the muscle fiber itself. Dysfunction at any point produces weakness with characteristic clinical features that allow localization.

The Motor Pathway

Component	Structure	Function
Upper Motor Neuron	Motor cortex (precentral gyrus) → corticospinal tract → descends through internal capsule, cerebral peduncle, pyramids → decussates at medullary pyramids → lateral corticospinal tract in spinal cord	Initiates voluntary movement; modulates and inhibits lower motor neuron activity; controls fine motor skills
Lower Motor Neuron	Anterior horn cells in spinal cord → ventral nerve roots → spinal nerves → peripheral nerves → terminal motor branches	Final common pathway for all motor activity; directly innervates muscle fibers; carries action potentials to neuromuscular junction
Neuromuscular Junction	Presynaptic terminal (acetylcholine vesicles) → synaptic cleft → postsynaptic membrane (nicotinic acetylcholine receptors)	Transmits signal from nerve to muscle; acetylcholine release triggers muscle fiber depolarization
Muscle Fiber	Sarcolemma → T-tubules → sarcoplasmic reticulum → myofibrils (actin and myosin filaments)	Excitation-contraction coupling; calcium-mediated cross-bridge cycling generates force

Mechanisms of Weakness by Anatomical Location

Central Nervous System (Upper Motor Neuron)

Cerebral Cortex and Internal Capsule

Mechanism: Disruption of corticospinal neurons in motor cortex or their axons in the internal capsule

Causes: Stroke, tumor, abscess, demyelination

Pattern: Contralateral hemiparesis (face, arm, leg); arm often more affected than leg in cortical lesions

Brainstem

Mechanism: Damage to corticospinal tracts before or after decussation; involvement of cranial nerve nuclei

Causes: Brainstem stroke, multiple sclerosis, tumor

Pattern: Crossed findings — ipsilateral cranial nerve palsy with contralateral hemiparesis

Spinal Cord

Mechanism: Damage to lateral corticospinal tract; anterior horn cells may also be involved

Causes: Trauma, transverse myelitis, compression, infarction

Pattern: Weakness at and below lesion level; often bilateral; associated sensory level

Peripheral Nervous System (Lower Motor Neuron)

Anterior Horn Cell

Mechanism: Degeneration of motor neuron cell bodies; loss of entire motor units

Causes: Amyotrophic lateral sclerosis, spinal muscular atrophy, poliomyelitis

Clinical features: Fasciculations, early atrophy, no sensory loss (motor neurons only)

Nerve Root (Radiculopathy)

Mechanism: Compression or inflammation of nerve root at or near the spinal column

Causes: Disc herniation, spondylosis, tumor, infection

Pattern: Myotomal weakness with dermatomal sensory loss; single or multiple roots

Peripheral Nerve (Neuropathy)

Mechanism: Axonal degeneration, demyelination, or both; affects motor and often sensory fibers

Causes: Diabetes, Guillain-Barré syndrome, hereditary neuropathies, toxins

Pattern: Length-dependent (distal greater than proximal) or multifocal; sensory symptoms common

Neuromuscular Junction

Condition	Mechanism	Key Features
Myasthenia Gravis	Autoantibodies against postsynaptic acetylcholine receptors (85%) or muscle-specific kinase (MuSK); reduced receptor density and impaired signal transmission	Fatigable weakness — worsens with repeated use, improves with rest; ptosis and diplopia common; no sensory loss; reflexes preserved
Lambert-Eaton Myasthenic Syndrome	Autoantibodies against presynaptic voltage-gated calcium channels; reduced acetylcholine release	Proximal weakness that improves with repeated effort (facilitation); autonomic symptoms; often paraneoplastic (small cell lung cancer)
Botulism	Botulinum toxin blocks presynaptic acetylcholine release by cleaving SNARE proteins	Descending paralysis; starts with cranial nerves (diplopia, dysphagia, dysarthria); dilated pupils; autonomic dysfunction

Muscle (Myopathy)

Type	Mechanism	Examples
Inflammatory Myopathies	Immune-mediated muscle fiber destruction; CD8+ T-cells (polymyositis, inclusion body myositis) or complement-mediated microangiopathy (dermatomyositis)	Polymyositis, dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy
Muscular Dystrophies	Genetic mutations affecting structural proteins (dystrophin, sarcoglycans, others); progressive muscle fiber degeneration and fibrosis	Duchenne and Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral dystrophy
Metabolic Myopathies	Defects in energy metabolism — glycogen storage, lipid metabolism, or mitochondrial function	McArdle disease (myophosphorylase deficiency), Pompe disease (acid maltase deficiency), mitochondrial myopathies
Toxic and Drug-Induced Myopathies	Direct muscle fiber toxicity, mitochondrial dysfunction, or immune-mediated damage	Statin myopathy, glucocorticoid myopathy, alcohol myopathy, colchicine myopathy
Endocrine Myopathies	Hormonal effects on muscle protein synthesis and degradation; electrolyte disturbances	Thyrotoxic myopathy, hypothyroid myopathy, Cushing syndrome myopathy, hypokalemic myopathy

How Specific Conditions Cause Muscle Weakness

Condition	Pathophysiological Mechanism	Treatment Implication
Guillain-Barré Syndrome	Post-infectious autoimmune attack on peripheral nerve myelin (AIDP) or axons (AMAN/AMSAN); demyelination causes conduction block and slowing	Immunotherapy (intravenous immunoglobulin or plasmapheresis) removes pathogenic antibodies; corticosteroids not effective
Amyotrophic Lateral Sclerosis	Progressive degeneration of both upper and lower motor neurons; exact mechanism unclear but involves protein aggregation, oxidative stress, and excitotoxicity	Riluzole (glutamate antagonist) provides modest survival benefit; supportive care is mainstay
Myasthenia Gravis	Antibody-mediated reduction in functional acetylcholine receptors at the neuromuscular junction	Acetylcholinesterase inhibitors increase available acetylcholine; immunosuppression reduces antibody production
Dermatomyositis	Complement-mediated destruction of intramuscular capillaries leading to muscle ischemia and perifascicular atrophy	Immunosuppression (corticosteroids, steroid-sparing agents) targets the autoimmune process
Hypokalemic Periodic Paralysis	Mutations in ion channels cause abnormal muscle membrane excitability; during attacks, potassium shifts intracellularly, hyperpolarizing muscle and preventing contraction	Potassium supplementation during attacks; acetazolamide for prophylaxis; avoid triggers (carbohydrate loads)
Critical Illness Myopathy	Combination of electrical silencing, catabolic state, immobilization, and medication effects (corticosteroids, neuromuscular blocking agents) causing myosin loss	Minimize corticosteroid and neuromuscular blocker use; early mobilization; nutritional support

Often Overlooked Mechanism: The “Second Wind” Phenomenon

In McArdle disease (glycogen storage disease type V), patients experience muscle pain and weakness during the first few minutes of exercise, followed by improvement — the “second wind.” This occurs because the initial exercise relies on glycogenolysis (blocked in McArdle disease), but after several minutes, blood flow increases and alternative fuel sources (free fatty acids, blood glucose) become available. Recognizing this pattern can prompt testing for myophosphorylase deficiency even when resting creatine kinase is only mildly elevated.

Clinical Application: Mixed Upper and Lower Motor Neuron Signs

The presence of both upper and lower motor neuron signs in the same patient is a critical finding that should immediately raise concern for amyotrophic lateral sclerosis. Look for hyperreflexia and spasticity (upper motor neuron) combined with fasciculations, atrophy, and weakness (lower motor neuron) in multiple body regions. No other common condition produces this combination, making it virtually pathognomonic when present.

3. History Taking

A comprehensive approach to eliciting the muscle weakness history

Red Flags — Require Urgent Evaluation

Respiratory muscle weakness — Dyspnea at rest, orthopnea, weak cough, unable to count to 20 in one breath (impending respiratory failure)
Rapidly ascending weakness — Suggests Guillain-Barré syndrome; may progress to respiratory failure within hours
Bulbar symptoms — Dysphagia, dysarthria, drooling (aspiration risk, possible myasthenic crisis or bulbar ALS)
Acute onset with headache or altered consciousness — Suggests stroke or intracranial pathology

Bladder or bowel dysfunction with weakness — Suggests spinal cord compression (cauda equina syndrome or myelopathy)
Fever with acute weakness — Consider infectious causes (viral myositis, epidural abscess, poliomyelitis)
Weakness after starting new medication — Drug-induced myopathy, serotonin syndrome, neuroleptic malignant syndrome
Dark urine with muscle pain — Rhabdomyolysis with risk of acute kidney injury

Systematic History: The “WEAKNESS” Approach

Use the mnemonic “WEAKNESS” to ensure comprehensive history taking:

W — Where is the weakness? Which muscles are affected? Proximal (shoulders, hips) or distal (hands, feet)? Symmetric or asymmetric? Face, eyes, or bulbar muscles involved?
E — Evolution and onset: When did it start? Sudden (seconds), rapid (hours to days), or gradual (weeks to months)? Is it progressive, static, or fluctuating?
A — Associated symptoms: Sensory changes (numbness, tingling)? Pain? Fatigue? Dysphagia? Diplopia? Ptosis? Respiratory difficulty? Bowel or bladder changes?
K — Key triggers and modifiers: Worse with activity (myasthenia) or rest? Time of day variation? Effect of temperature? Triggered by exercise, fasting, or carbohydrates?
N — Neurological review: Cognitive changes? Cranial nerve symptoms? Coordination problems? Gait disturbance? Previous similar episodes?
E — Exposures and medications: Recent infections? New medications (statins, steroids, chemotherapy)? Toxins? Alcohol? Illicit drugs?
S — Systemic and past history: Autoimmune diseases? Thyroid disorders? Diabetes? Malignancy? Family history of neuromuscular disease?
S — Social and functional impact: Activities affected? Falling? Difficulty with stairs, rising from chairs, gripping objects? Occupation? Need for assistive devices?

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Myasthenia Gravis	Fatigable weakness, ptosis, diplopia, bulbar symptoms, worse later in day	“Does your weakness get worse as the day goes on or with repeated activity, and improve after rest?”
Guillain-Barré Syndrome	Ascending weakness, areflexia, recent infection, paresthesias	“Did you have a respiratory or gastrointestinal infection in the past 1 to 4 weeks before the weakness started?”
Inflammatory Myopathy (Polymyositis, Dermatomyositis)	Proximal weakness, difficulty climbing stairs or rising from chairs, skin rash	“Do you have difficulty getting up from a low chair without using your arms, or trouble climbing stairs or lifting things overhead?”
Motor Neuron Disease (Amyotrophic Lateral Sclerosis)	Progressive weakness, fasciculations, mixed upper and lower motor neuron signs, no sensory loss	“Have you noticed muscle twitching under your skin, or has your speech or swallowing changed?”
Peripheral Neuropathy	Distal weakness, sensory symptoms (numbness, burning, tingling), foot drop	“Do you have numbness or tingling in your hands or feet along with the weakness? Do you trip or drag your feet?”
Spinal Cord Compression	Weakness below a level, sensory level, bowel or bladder dysfunction, back pain	“Do you have back pain? Have you noticed any changes in your bladder or bowel control, or numbness below a certain level on your body?”
Stroke	Sudden onset, unilateral weakness, facial droop, speech difficulty	“Did the weakness come on suddenly? Can you tell me exactly what you were doing when it started?”
Lambert-Eaton Myasthenic Syndrome	Proximal weakness that improves with activity, dry mouth, smoking history	“Does your strength seem to get better after you’ve been using the muscle for a while? Do you have a very dry mouth or difficulty with erections?”
Periodic Paralysis	Episodic weakness, triggered by rest after exercise, carbohydrates, or potassium changes	“Do you have episodes of weakness that come and go, especially after heavy exercise or eating a large meal?”
Statin Myopathy	Proximal weakness and myalgias after starting statin, elevated creatine kinase	“When did you start taking a cholesterol medication? Did the weakness or muscle pain begin after starting it?”
Hypothyroid Myopathy	Proximal weakness, fatigue, cold intolerance, weight gain, constipation	“Have you had any changes in your weight, energy level, or tolerance to cold temperatures?”
Inclusion Body Myositis	Older patient, asymmetric weakness, finger flexors and quadriceps affected, dysphagia	“Do you have trouble gripping things or opening jars? Is one side weaker than the other?”

Medication and Exposure History

Medications That Cause Muscle Weakness

Statins (HMG-CoA reductase inhibitors) — Myalgia, myopathy, rarely rhabdomyolysis; risk increased with higher doses, drug interactions (fibrates, azole antifungals)
Corticosteroids — Steroid myopathy with chronic use; proximal weakness, especially hip flexors; dose and duration dependent
Colchicine — Neuromyopathy, especially with renal impairment; affects both nerves and muscles
Chloroquine and Hydroxychloroquine — Vacuolar myopathy with prolonged use; may also cause neuropathy
Zidovudine (AZT) — Mitochondrial myopathy with prolonged use
Amiodarone — Can cause both myopathy and neuropathy
Immune checkpoint inhibitors — Immune-mediated myositis, myasthenia gravis, or overlap syndromes
D-Penicillamine — Can induce myasthenia gravis or polymyositis
Neuromuscular blocking agents — Prolonged weakness in ICU patients (critical illness myopathy)

Social, Occupational, and Family History

Alcohol: Chronic alcoholic myopathy (proximal weakness); acute alcoholic myopathy with rhabdomyolysis after binge drinking
Illicit drugs: Cocaine, heroin, amphetamines can cause rhabdomyolysis
Occupation: Lead exposure (wrist drop), organophosphate exposure (cholinergic crisis)
Recent travel: Poliomyelitis (unvaccinated, endemic areas), tick paralysis, botulism
Diet: Licorice ingestion (hypokalemia), undercooked meat (trichinosis)
Family history: Muscular dystrophies, hereditary neuropathies (Charcot-Marie-Tooth), periodic paralysis, myotonic dystrophy — ask about relatives who use wheelchairs, have gait problems, or died young
Recent infection: Guillain-Barré syndrome (Campylobacter, CMV, EBV, Zika), viral myositis (influenza, COVID-19), post-polio syndrome

Functional Assessment Questions

Function	Question to Ask	What It Tests
Rising from chair	“Can you get up from a chair without using your arms?”	Hip flexor and quadriceps strength (proximal lower extremity)
Climbing stairs	“Can you climb stairs without using the handrail? How many flights?”	Hip and knee extensors, overall lower extremity strength
Overhead activities	“Can you reach into high cupboards or comb your hair without difficulty?”	Shoulder abductors and flexors (proximal upper extremity)
Fine motor tasks	“Do you have trouble buttoning shirts, turning keys, or opening jars?”	Hand intrinsic muscles, grip strength (distal upper extremity)
Walking and balance	“Do you trip or fall? Do you need to hold onto furniture or walls?”	Ankle dorsiflexors (foot drop), overall gait stability
Respiratory function	“Do you get short of breath lying flat? Is your voice weaker at the end of sentences?”	Diaphragm and accessory respiratory muscles
Swallowing	“Do you choke on food or liquids? Does food get stuck?”	Bulbar muscles (pharyngeal weakness)

4. Physical Examination

A systematic approach for evaluating muscle weakness

Systematic Framework: The neurological examination for weakness follows a structured approach: Inspection → Tone → Power → Reflexes → Sensation → Coordination → Gait. The goal is to localize the lesion along the motor pathway (upper motor neuron, lower motor neuron, neuromuscular junction, or muscle) before generating a differential diagnosis.

General Inspection

Body habitus: Cushingoid appearance (steroid myopathy), cachexia (malignancy, motor neuron disease), obesity (obstructive sleep apnea contributing to fatigue)
Posture: Hyperlordosis (proximal weakness compensation), scoliosis (longstanding neuromuscular disease), head drop (neck extensor weakness)
Respiratory pattern: Use of accessory muscles, paradoxical abdominal breathing (diaphragmatic weakness), tachypnea
Skin: Heliotrope rash around eyes, Gottron papules over knuckles (dermatomyositis), café-au-lait spots (neurofibromatosis), erythema nodosum (sarcoidosis)
Muscle bulk: Atrophy (denervation or disuse), pseudohypertrophy (Duchenne muscular dystrophy — enlarged calves with fatty replacement)
Fasciculations: Visible twitching under the skin (lower motor neuron disease, especially amyotrophic lateral sclerosis)
Ptosis: Unilateral or bilateral drooping eyelids (myasthenia gravis, Horner syndrome, third nerve palsy)

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Respiratory Rate and Pattern	Tachypnea, use of accessory muscles, inability to speak in full sentences, paradoxical breathing	Respiratory muscle weakness; impending respiratory failure in Guillain-Barré syndrome or myasthenic crisis
Oxygen Saturation	Hypoxemia, especially when supine	Diaphragmatic weakness; may be normal until late in respiratory failure
Heart Rate	Tachycardia, bradycardia, arrhythmia	Autonomic dysfunction (Guillain-Barré syndrome), thyroid disease, electrolyte abnormalities
Blood Pressure	Hypertension, hypotension, orthostatic changes, labile blood pressure	Autonomic instability (Guillain-Barré syndrome), hypertensive emergency with stroke
Temperature	Fever	Infectious etiology (viral myositis, epidural abscess), inflammatory myopathy, neuroleptic malignant syndrome

Bedside Respiratory Assessment

Critical Assessment — Do Not Skip

Respiratory failure is the leading cause of death in acute neuromuscular weakness. Perform these bedside tests in all patients with acute weakness:

Single breath count: Ask patient to take a deep breath and count as high as possible — normal is greater than 20; less than 10 suggests severe weakness
Forced vital capacity (FVC): Less than 20 mL/kg or declining suggests need for ICU monitoring (the “20/30/40 rule” — FVC less than 20, MIP less than 30, MEP less than 40)
Negative inspiratory force (NIF/MIP): Less than -30 cm H₂O indicates significant diaphragmatic weakness
Paradoxical breathing: Abdomen moves inward during inspiration (diaphragm paralysis)
Orthopnea: Ask about breathing difficulty when lying flat

Cranial Nerve Examination

Cranial Nerve	Test	Abnormal Finding	Suggests
II, III (Pupils)	Pupillary light reflex	Dilated, poorly reactive pupils	Botulism, Miller Fisher syndrome
III, IV, VI (Eye movements)	Extraocular movements, pursuit, saccades	Ophthalmoplegia, diplopia	Myasthenia gravis, Miller Fisher syndrome, botulism, brainstem lesion
III (Levator palpebrae)	Observe eyelid position; fatigability test (sustained upgaze for 60 seconds)	Ptosis, worsening with sustained upgaze	Myasthenia gravis (fatigable), Horner syndrome, third nerve palsy
V (Trigeminal)	Facial sensation, jaw strength, corneal reflex	Facial numbness, weak jaw closure	Brainstem lesion, trigeminal neuropathy
VII (Facial)	Facial symmetry, smile, eye closure, forehead wrinkling	Facial weakness (upper vs lower face pattern)	Upper motor neuron (forehead spared) vs lower motor neuron (entire face affected)
IX, X (Bulbar)	Palate elevation (“say ahh”), gag reflex, voice quality	Nasal speech, palate asymmetry, absent gag, pooling of secretions	Bulbar weakness — myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome
XI (Accessory)	Shoulder shrug, head turn against resistance	Weak sternocleidomastoid or trapezius	Accessory nerve palsy, motor neuron disease
XII (Hypoglossal)	Tongue protrusion, inspection for atrophy and fasciculations	Tongue deviation, atrophy, fasciculations	Lower motor neuron: tongue deviates toward weak side; amyotrophic lateral sclerosis if fasciculations present

Motor Examination

Inspection for Atrophy and Fasciculations

Compare muscle bulk bilaterally; look for asymmetry
Check thenar and hypothenar eminences (hand intrinsics), first dorsal interosseous, quadriceps, gastrocnemius
Observe for fasciculations at rest — spontaneous, irregular twitching visible under skin (best seen in tongue, deltoid, quadriceps)
Percussion of muscle may provoke fasciculations in motor neuron disease

Tone Assessment

Finding	Description	Indicates
Spasticity	Velocity-dependent increase in tone; “clasp-knife” quality (initial resistance then gives way)	Upper motor neuron lesion (stroke, spinal cord disease, multiple sclerosis)
Rigidity	Increased tone throughout range of motion; “lead pipe” or “cogwheel” (with tremor)	Extrapyramidal disease (Parkinson disease, drug-induced parkinsonism)
Hypotonia/Flaccidity	Reduced resistance to passive movement; floppy limbs	Lower motor neuron lesion, acute upper motor neuron lesion (spinal shock), cerebellar disease, myopathy
Myotonia	Delayed relaxation after muscle contraction; “grip myotonia” — difficulty releasing handshake	Myotonic dystrophy, myotonia congenita

Strength Testing — Medical Research Council (MRC) Scale

Grade	Description
5	Normal power against full resistance
4	Active movement against gravity and resistance (can subdivide: 4+, 4, 4-)
3	Active movement against gravity only (no added resistance)
2	Active movement with gravity eliminated (horizontal plane only)
1	Flicker or trace of contraction visible or palpable
0	No contraction

Key Muscles to Test by Region

Upper Extremity

Proximal:

Shoulder abduction (C5) — Deltoid
Elbow flexion (C5-C6) — Biceps
Elbow extension (C7) — Triceps

Distal:

Wrist extension (C6-C7) — Extensor carpi radialis
Finger extension (C7) — Extensor digitorum
Finger abduction (T1) — First dorsal interosseous
Thumb abduction (T1) — Abductor pollicis brevis

Lower Extremity

Proximal:

Hip flexion (L1-L2) — Iliopsoas
Hip abduction (L4-L5) — Gluteus medius
Knee extension (L3-L4) — Quadriceps
Knee flexion (L5-S1) — Hamstrings

Distal:

Ankle dorsiflexion (L4-L5) — Tibialis anterior
Great toe extension (L5) — Extensor hallucis longus
Ankle plantarflexion (S1-S2) — Gastrocnemius

Special Tests and Maneuvers

Test	How to Perform	Positive Finding	Significance
Gower sign	Ask patient to rise from sitting on floor	Patient “walks up” their own legs using hands on thighs	Proximal (hip girdle) weakness — myopathy, especially muscular dystrophy
Fatigability test	Sustained upgaze for 60-90 seconds; repeated grip strength	Progressive ptosis or weakening grip with repetition	Myasthenia gravis — weakness worsens with sustained effort
Ice pack test	Apply ice to closed eyelid for 2 minutes	Improvement of ptosis after cooling	Suggestive of myasthenia gravis (cold inhibits acetylcholinesterase)
Cogan lid twitch	Ask patient to look down for 15 seconds, then quickly look up	Eyelid overshoots then falls back	Myasthenia gravis
Curtain sign (orbicularis oculi)	Ask patient to close eyes tightly while you try to open them	Lashes visible when eyes closed (“peek sign”) or weak eye closure	Myasthenia gravis, facial weakness
Pronator drift	Arms extended, palms up, eyes closed for 20-30 seconds	Arm pronates and drifts downward	Upper motor neuron weakness (corticospinal tract lesion)
Finger roll test	Ask patient to rotate extended index fingers around each other	One finger moves slowly or erratically	Subtle upper motor neuron weakness
Heel-to-shin test	Run heel smoothly down opposite shin from knee to ankle	Irregular, jerky movement or inability to perform	Cerebellar dysfunction or weakness

Deep Tendon Reflexes

Reflex	Nerve Root	Grading Scale
Biceps	C5-C6	0 — Absent 1+ — Diminished 2+ — Normal 3+ — Brisk (may be normal) 4+ — Clonus (pathological)
Brachioradialis	C5-C6
Triceps	C7-C8
Patellar (knee jerk)	L3-L4
Achilles (ankle jerk)	S1-S2
Jaw jerk	CN V (trigeminal)

Pathological Reflexes

Babinski sign: Stroke lateral sole from heel to toes; positive = great toe extension with fanning of other toes (upper motor neuron lesion)
Hoffman sign: Flick distal phalanx of middle finger downward; positive = thumb and index finger flexion (upper motor neuron lesion)
Clonus: Sustained rhythmic contractions with sudden dorsiflexion of ankle or wrist; indicates upper motor neuron lesion

Sensory Examination

Why Test Sensation in a Weakness Workup?

Sensory findings help localize the lesion:

Pure motor findings (no sensory loss): Motor neuron disease, pure motor neuropathy, neuromuscular junction disorder, myopathy
Sensory loss in dermatomal pattern: Radiculopathy
Glove-and-stocking sensory loss: Peripheral polyneuropathy
Sensory level on trunk: Spinal cord lesion
Hemisensory loss: Contralateral brain or brainstem lesion

Gait Examination

Gait Pattern	Description	Suggests
Waddling gait	Side-to-side trunk sway, exaggerated lumbar lordosis	Proximal (hip girdle) weakness — myopathy
Steppage gait	High knee lift to clear foot due to foot drop; slapping of foot on ground	Ankle dorsiflexor weakness — peroneal neuropathy, L5 radiculopathy, peripheral neuropathy
Spastic gait	Stiff, circumducting leg; scissoring in severe cases	Upper motor neuron lesion — stroke, spinal cord disease
Ataxic gait	Wide-based, unsteady, irregular steps	Cerebellar dysfunction or sensory ataxia (proprioceptive loss)
Trendelenburg gait	Pelvis drops on the unsupported side during single-leg stance	Hip abductor weakness (gluteus medius)

Expected Findings by Etiology

Condition	Distribution	Tone	Reflexes	Atrophy	Sensory	Other Findings
Stroke	Hemiparesis (face, arm, leg)	↑ Spasticity (delayed)	↑ Hyperreflexia	Minimal (late)	Hemisensory loss possible	Babinski positive, facial weakness (UMN pattern)
Guillain-Barré Syndrome	Ascending, symmetric	↓ Flaccid	↓ Areflexia	Minimal (acute)	Paresthesias, mild sensory loss	Autonomic instability, respiratory weakness
Motor Neuron Disease (ALS)	Asymmetric, spreads	Mixed: ↑ and ↓	Mixed: ↑ and ↓	Prominent	Absent	Fasciculations, bulbar signs, UMN + LMN signs together
Myasthenia Gravis	Ocular, bulbar, proximal	Normal	Normal	Absent	Absent	Fatigable weakness, ptosis, diplopia
Inflammatory Myopathy	Proximal, symmetric	Normal to ↓	Normal to ↓	Variable	Absent	Skin rash (dermatomyositis), dysphagia
Peripheral Polyneuropathy	Distal, symmetric	↓	↓ (distal first)	Distal atrophy	Glove-and-stocking	Foot drop, steppage gait
Spinal Cord Compression	Below lesion level	↑ Below level	↑ Below level	Minimal	Sensory level	Bowel and bladder dysfunction, Babinski positive

Important Teaching Point

The pattern of weakness matters more than the severity. A detailed motor examination that accurately localizes the weakness to upper motor neuron, lower motor neuron, neuromuscular junction, or muscle will dramatically narrow the differential diagnosis. Pay close attention to:

Proximal versus distal distribution
Symmetric versus asymmetric involvement
Presence or absence of sensory findings
Reflex pattern (increased versus decreased)
Presence of fasciculations or atrophy

These five features together will localize most cases of weakness before any investigations are ordered.

5. Differential Diagnosis

Systematic approach organized by probability, duration, and anatomical localization

Acute Muscle Weakness (Hours to Days)

Probability	Condition	Key Features	Red Flags
COMMON	Stroke (ischemic or hemorrhagic)	Sudden onset hemiparesis, facial droop, speech difficulty, vascular risk factors	Sudden onset, headache, altered consciousness, time-critical for thrombolysis
COMMON	Guillain-Barré Syndrome	Ascending symmetric weakness over days, areflexia, preceding infection 1-4 weeks prior, paresthesias	Rapid progression, respiratory involvement, autonomic instability
COMMON	Acute radiculopathy (disc herniation)	Dermatomal weakness with radicular pain, sensory loss, reduced reflex in affected root	Cauda equina syndrome: bilateral leg weakness, saddle anesthesia, urinary retention
LESS COMMON	Myasthenic crisis	Severe generalized weakness in known myasthenia gravis, often triggered by infection or medication	Respiratory failure, inability to clear secretions, requires ICU
LESS COMMON	Acute transverse myelitis	Bilateral weakness with sensory level, bowel and bladder dysfunction, back pain	Rapid progression, may indicate spinal cord compression requiring emergent imaging
LESS COMMON	Hypokalemic or hyperkalemic periodic paralysis	Episodic weakness, often after heavy exercise, large carbohydrate meal, or potassium shifts	Cardiac arrhythmias with severe potassium abnormalities
LESS COMMON	Rhabdomyolysis	Muscle pain, weakness, dark urine, elevated creatine kinase (often greater than 10,000 U/L)	Acute kidney injury, hyperkalemia, compartment syndrome
UNCOMMON BUT SERIOUS	Spinal cord compression (epidural abscess, metastasis, hematoma)	Back pain, weakness below level, sensory level, sphincter dysfunction	Surgical emergency — irreversible paralysis if not decompressed within hours
UNCOMMON BUT SERIOUS	Botulism	Descending paralysis starting with cranial nerves (diplopia, dysphagia), dilated pupils, autonomic symptoms	Respiratory failure, food-borne or wound source
UNCOMMON BUT SERIOUS	Tick paralysis	Ascending flaccid paralysis, areflexia, recent outdoor exposure, attached tick often found on scalp	Respiratory failure; rapid recovery after tick removal

Subacute Muscle Weakness (Weeks to Months)

Step-by-Step Approach to Subacute Weakness:

Step 1: Rule out medication-induced causes — Review all medications, especially statins, corticosteroids, and immune checkpoint inhibitors
Step 2: Consider inflammatory and autoimmune etiologies — Often treatable if identified early
Step 3: Evaluate for malignancy — Paraneoplastic syndromes and direct tumor involvement
Step 4: Check metabolic and endocrine causes — Thyroid function, electrolytes, vitamin levels

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Inflammatory myopathies (dermatomyositis, polymyositis, immune-mediated necrotizing myopathy)	Most common cause of subacute proximal weakness in adults	Symmetric proximal weakness, elevated creatine kinase, skin rash in dermatomyositis (heliotrope, Gottron papules)
COMMON	Drug-induced myopathy (statins, corticosteroids)	Up to 10% of statin users report myalgias; true myopathy less common	Temporal relationship to medication initiation or dose increase; often improves with discontinuation
COMMON	Chronic inflammatory demyelinating polyneuropathy (CIDP)	Most common treatable chronic neuropathy	Progressive symmetric proximal and distal weakness, areflexia, sensory involvement, nerve conduction slowing
LESS COMMON	Thyroid myopathy (hypothyroid or hyperthyroid)	Myopathy present in up to 80% of hypothyroid patients	Hypothyroid: proximal weakness, delayed relaxation of reflexes, elevated CK. Hyperthyroid: proximal weakness with normal or low CK
LESS COMMON	Subacute combined degeneration (vitamin B12 deficiency)	Increasingly recognized, especially in elderly and post-bariatric surgery	Weakness with prominent sensory ataxia, paresthesias, cognitive changes, macrocytic anemia
LESS COMMON	Lambert-Eaton myasthenic syndrome	60% associated with small cell lung cancer	Proximal weakness that improves with activity (facilitation), dry mouth, hyporeflexia improving after exercise
UNCOMMON BUT SERIOUS	Paraneoplastic syndromes	May precede cancer diagnosis by months to years	Subacute onset, may have associated antibodies (anti-Hu, anti-Yo), search for occult malignancy
UNCOMMON BUT SERIOUS	HIV-associated myopathy or neuropathy	Common in untreated HIV; also antiretroviral-related	Risk factors for HIV, may have other HIV manifestations

Chronic Muscle Weakness (Greater than 6 Months)

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Diabetic polyneuropathy	Affects 50% of diabetic patients over time	Length-dependent, distal greater than proximal, sensory symptoms prominent, foot drop in severe cases
COMMON	Myasthenia gravis	Prevalence approximately 20 per 100,000	Fatigable weakness, ocular symptoms (ptosis, diplopia), bulbar weakness, diurnal variation (worse later in day)
COMMON	Chronic radiculopathy or spinal stenosis	Very common in elderly population	Dermatomal weakness, neurogenic claudication (stenosis), back or neck pain
LESS COMMON	Amyotrophic lateral sclerosis (ALS)	Incidence 2-3 per 100,000 per year	Progressive weakness with mixed upper and lower motor neuron signs, fasciculations, no sensory loss, bulbar involvement
LESS COMMON	Inclusion body myositis	Most common acquired myopathy in patients over 50	Asymmetric weakness, finger flexors and quadriceps preferentially affected, dysphagia, poor response to immunotherapy
LESS COMMON	Hereditary neuropathies (Charcot-Marie-Tooth disease)	Most common inherited neuromuscular disorder	Distal weakness, high arches (pes cavus), hammer toes, family history, slowly progressive since childhood
LESS COMMON	Muscular dystrophies (limb-girdle, facioscapulohumeral)	Variable; FSHD affects 1 in 8,000-20,000	Proximal weakness, characteristic patterns (scapular winging in FSHD), family history, slowly progressive
UNCOMMON BUT SERIOUS	Myotonic dystrophy	Most common adult muscular dystrophy (1 in 8,000)	Myotonia (grip myotonia, percussion myotonia), distal weakness, cataracts, cardiac conduction abnormalities, characteristic facies
UNCOMMON BUT SERIOUS	Metabolic myopathies (Pompe disease, McArdle disease)	Rare but treatable (enzyme replacement for Pompe)	Exercise intolerance, second-wind phenomenon (McArdle), respiratory involvement (late-onset Pompe)

Anatomical Localization Approach

Upper Motor Neuron (Brain and Spinal Cord)

Stroke

Multiple sclerosis

Spinal cord compression

Transverse myelitis

Amyotrophic lateral sclerosis (UMN component)

Primary lateral sclerosis

Hereditary spastic paraplegia

Lower Motor Neuron (Anterior Horn and Nerve)

Amyotrophic lateral sclerosis (LMN component)

Spinal muscular atrophy

Poliomyelitis and post-polio syndrome

Radiculopathy

Plexopathy

Peripheral polyneuropathy

Mononeuropathy (carpal tunnel, peroneal)

Guillain-Barré syndrome

CIDP

Neuromuscular Junction

Myasthenia gravis

Lambert-Eaton myasthenic syndrome

Botulism

Organophosphate poisoning

Drug-induced (aminoglycosides, magnesium)

Congenital myasthenic syndromes

Muscle (Myopathy)

Inflammatory myopathies

Muscular dystrophies

Toxic and drug-induced myopathies

Endocrine myopathies

Metabolic myopathies

Infectious myositis

Critical illness myopathy

Inclusion body myositis

Drug-Induced Muscle Weakness

Drug or Drug Class	Mechanism	Characteristics	Time to Resolution After Stopping
Statins (HMG-CoA reductase inhibitors)	Mitochondrial dysfunction, CoQ10 depletion, immune-mediated (anti-HMGCR antibodies)	Myalgias common; true myopathy with elevated CK less common; immune-mediated form may not resolve	Weeks to months for toxic myopathy; immune-mediated may persist
Corticosteroids	Increased protein catabolism, decreased protein synthesis, type II fiber atrophy	Proximal weakness (especially hip flexors), normal CK, dose and duration dependent	Months (may take 3-6 months for full recovery)
Colchicine	Disruption of microtubule function affecting both nerve and muscle	Neuromyopathy with proximal weakness and neuropathy; elevated CK; risk increases with renal impairment	Weeks to months
Chloroquine and Hydroxychloroquine	Lysosomal dysfunction causing vacuolar myopathy	Slowly progressive proximal weakness; may also cause neuropathy and cardiomyopathy	Months to years; may be irreversible
Zidovudine (AZT)	Mitochondrial toxicity (inhibits mitochondrial DNA polymerase gamma)	Proximal myopathy, elevated CK, ragged red fibers on biopsy	Weeks to months
Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)	Immune-mediated inflammation; may cause myositis, myasthenia gravis, or overlap	Can be severe; may have concurrent myocarditis; check troponin	Variable; may require immunosuppression
Fibrates (gemfibrozil, fenofibrate)	Similar to statins; risk markedly increased when combined with statins	Myopathy and rhabdomyolysis, especially with statin combination	Weeks
Amiodarone	Lysosomal dysfunction; may also cause neuropathy	Proximal myopathy; long half-life prolongs toxicity	Months (very long half-life)
D-Penicillamine	Immune-mediated; can induce myasthenia gravis or polymyositis	May develop autoantibodies; clinical syndrome identical to idiopathic forms	Months; may persist after discontinuation
Alcohol	Direct toxicity, nutritional deficiency, electrolyte disturbances	Acute: rhabdomyolysis after binge. Chronic: progressive proximal myopathy	Months with abstinence; may not fully recover

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Sudden hemiparesis with facial droop	Stroke	Emergent CT head, activate stroke protocol
Ascending weakness with areflexia after viral illness	Guillain-Barré syndrome	Lumbar puncture (albuminocytologic dissociation), nerve conduction studies, monitor respiratory function
Fatigable ptosis and diplopia worse in evening	Myasthenia gravis	Acetylcholine receptor antibodies, ice pack test, repetitive nerve stimulation
Proximal weakness with heliotrope rash	Dermatomyositis	CK, myositis-specific antibodies, EMG, muscle biopsy, malignancy screening
Mixed UMN and LMN signs with fasciculations, no sensory loss	Amyotrophic lateral sclerosis	EMG (widespread denervation), MRI to exclude structural lesions
Weakness below a level with sensory level and bladder dysfunction	Spinal cord compression	Emergent MRI spine, neurosurgical consultation
Proximal weakness in patient on statin	Statin myopathy	Check CK, stop statin, reassess in 4-6 weeks; if persistent, check anti-HMGCR antibodies
Distal weakness with sensory loss in glove-and-stocking pattern	Peripheral polyneuropathy	Glucose, HbA1c, B12, TSH, SPEP, nerve conduction studies
Descending paralysis with dilated pupils after eating canned food	Botulism	Stool and serum for botulinum toxin, EMG, antitoxin administration
Episodic weakness after large carbohydrate meal	Hypokalemic periodic paralysis	Check potassium during attack, genetic testing, trial of potassium
Older patient with asymmetric weakness affecting finger flexors and quadriceps	Inclusion body myositis	CK (often only mildly elevated), EMG, muscle biopsy (rimmed vacuoles)
Proximal weakness improving with repeated effort, dry mouth, smoking history	Lambert-Eaton myasthenic syndrome	Voltage-gated calcium channel antibodies, EMG with repetitive stimulation, CT chest for malignancy

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical localization

Baseline Investigations for All Patients with Unexplained Weakness

Investigation	Purpose	What to Look For	Practical Points
Complete blood count	Screen for anemia, infection, hematologic malignancy	Macrocytic anemia (B12 deficiency), lymphopenia (HIV, autoimmune)	May be normal in many neuromuscular diseases
Comprehensive metabolic panel	Electrolytes, renal and liver function	Hypokalemia, hyperkalemia, hypercalcemia, hypomagnesemia, renal failure	Potassium critical in periodic paralysis; check during attack if episodic
Creatine kinase (CK)	Marker of muscle damage	Elevated: myopathy, rhabdomyolysis, motor neuron disease. Normal: neuropathy, NMJ disorders, steroid myopathy	Can be elevated after vigorous exercise, IM injections, or EMG; repeat if borderline
Thyroid function tests (TSH, free T4)	Screen for thyroid myopathy	Hypothyroidism (weakness, elevated CK, delayed reflexes) or hyperthyroidism (weakness, normal CK)	Thyroid disease is common and treatable cause of weakness
Vitamin B12 level	Screen for subacute combined degeneration	Low B12 with weakness, sensory ataxia, and cognitive changes	Check methylmalonic acid if B12 borderline low (200-400 pg/mL)
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)	Screen for inflammatory conditions	Elevated in inflammatory myopathies, vasculitis, infections	May be normal in some inflammatory myopathies
Hemoglobin A1c or fasting glucose	Screen for diabetes (common cause of neuropathy)	Diabetes or prediabetes	Diabetic neuropathy can occur even with prediabetes

Targeted Investigations by Suspected Localization

If Suspecting Upper Motor Neuron Lesion (Brain or Spinal Cord)

First-Line Tests

CT head (non-contrast): Immediate if acute stroke suspected; identifies hemorrhage within minutes
MRI brain with and without contrast: Gold standard for stroke (diffusion-weighted imaging), demyelination, tumor, infection
MRI spine with and without contrast: Essential for myelopathy; identifies compression, transverse myelitis, demyelination

Second-Line Tests

Lumbar puncture: If infection, inflammation, or demyelination suspected; CSF analysis for cells, protein, oligoclonal bands
MR angiography or CT angiography: If vascular lesion suspected
Visual evoked potentials: Evidence of demyelination (multiple sclerosis)
Aquaporin-4 (NMO-IgG) and MOG antibodies: If neuromyelitis optica spectrum disorder suspected

If Suspecting Lower Motor Neuron Lesion (Anterior Horn Cell, Nerve Root, Peripheral Nerve)

First-Line Tests

Electromyography (EMG) and nerve conduction studies (NCS): Distinguishes neuropathy from myopathy; identifies denervation, demyelination, conduction block
MRI spine: For radiculopathy — identifies disc herniation, foraminal stenosis, tumor
Lumbar puncture: For Guillain-Barré syndrome (albuminocytologic dissociation: elevated protein, normal cells)

Second-Line Tests

Serum protein electrophoresis (SPEP) and immunofixation: Screen for paraproteinemia associated with neuropathy
Anti-ganglioside antibodies (GM1, GD1a, GQ1b): Guillain-Barré syndrome variants, multifocal motor neuropathy
Genetic testing: Hereditary neuropathies (Charcot-Marie-Tooth — PMP22 duplication most common)
Nerve biopsy: Rarely needed; consider for vasculitic neuropathy, amyloidosis

If Suspecting Neuromuscular Junction Disorder

For Myasthenia Gravis

Acetylcholine receptor (AChR) antibodies: Positive in 85% of generalized MG, 50% of ocular MG
Muscle-specific kinase (MuSK) antibodies: Positive in 40% of AChR-negative MG
LRP4 antibodies: Consider if AChR and MuSK negative
Repetitive nerve stimulation: Decremental response (greater than 10% decrement) supports diagnosis
Single-fiber EMG: Most sensitive test; increased jitter
CT chest: Screen for thymoma (present in 10-15% of MG patients)

For Lambert-Eaton Myasthenic Syndrome

Voltage-gated calcium channel (VGCC) antibodies: Positive in greater than 90%
Repetitive nerve stimulation: Incremental response (greater than 100% increment at high-frequency stimulation)
CT chest, abdomen, pelvis: Search for small cell lung cancer (present in 50-60%)
PET-CT: If CT negative but high clinical suspicion for malignancy

If Suspecting Myopathy

First-Line Tests

Creatine kinase: Often markedly elevated (5-50 times normal) in inflammatory and dystrophic myopathies; may be normal in steroid myopathy
Aldolase: May be elevated even when CK is normal (especially in dermatomyositis)
EMG: Myopathic pattern (small, polyphasic motor units with early recruitment); helps distinguish from neuropathy
MRI of affected muscles: Shows edema in active inflammation; helps guide biopsy site

Second-Line Tests

Myositis-specific antibodies panel: Anti-Jo-1 (antisynthetase syndrome), anti-Mi-2 (dermatomyositis), anti-SRP, anti-HMGCR (immune-mediated necrotizing myopathy), anti-MDA5
Muscle biopsy: Gold standard for diagnosis; shows inflammation, necrosis, dystrophic changes, specific patterns
Genetic testing: For suspected muscular dystrophies (dystrophin gene for Duchenne/Becker, others based on phenotype)
Malignancy screening: CT chest, abdomen, pelvis; consider PET-CT (dermatomyositis has strong cancer association)

Understanding EMG and Nerve Conduction Studies

Finding	Neuropathy	Myopathy	Neuromuscular Junction	Motor Neuron Disease
Motor nerve conduction velocity	Slowed (demyelinating) or normal (axonal)	Normal	Normal	Normal or mildly reduced
Compound muscle action potential (CMAP) amplitude	Reduced (axonal) or normal (demyelinating)	Normal or reduced	Reduced	Reduced
Sensory nerve action potential (SNAP)	Abnormal	Normal	Normal	Normal
Spontaneous activity (fibrillations, positive sharp waves)	Present in axonal	Present in inflammatory myopathies	Absent	Present (widespread)
Motor unit potentials	Large, polyphasic (chronic reinnervation)	Small, polyphasic, early recruitment	Normal morphology, varying amplitude	Large, polyphasic with reduced recruitment
Repetitive nerve stimulation	Normal	Normal	Decrement (MG) or increment (LEMS)	Normal

Special Investigations

Lumbar Puncture — When to Perform

Indication	Expected CSF Finding	Clinical Significance
Guillain-Barré syndrome	Elevated protein (greater than 45 mg/dL), normal cell count (albuminocytologic dissociation)	Supports diagnosis; may be normal in first week
CIDP	Elevated protein, normal cells	Similar to GBS but chronic course
Multiple sclerosis	Oligoclonal bands (present in CSF, absent in serum), elevated IgG index	Supports demyelinating disease
CNS infection	Pleocytosis, elevated protein, glucose depends on organism	Bacterial (neutrophils, low glucose), viral (lymphocytes, normal glucose)
Carcinomatous meningitis	Malignant cells on cytology, elevated protein	May require multiple LPs; consider MRI spine with contrast

Muscle Biopsy — Indications and Findings

Condition	Characteristic Biopsy Findings
Polymyositis	Endomysial inflammation with CD8+ T-cells, muscle fiber necrosis and regeneration
Dermatomyositis	Perifascicular atrophy, perivascular inflammation, complement deposition on capillaries
Inclusion body myositis	Rimmed vacuoles, endomysial inflammation, congophilic inclusions
Immune-mediated necrotizing myopathy	Prominent necrosis with minimal inflammation, macrophage infiltration
Muscular dystrophy	Variation in fiber size, fibrosis, fatty replacement; immunohistochemistry for specific proteins (dystrophin)
Mitochondrial myopathy	Ragged red fibers (modified Gomori trichrome), cytochrome oxidase-negative fibers

Empiric Treatment Trials as Diagnostic Tools

In some situations, response to treatment supports the diagnosis:

Pyridostigmine trial: Improvement supports myasthenia gravis (use with caution; edrophonium test rarely used now due to cardiac risks)
Thyroid hormone replacement: Improvement in weakness supports hypothyroid myopathy
Statin discontinuation: Resolution of weakness within weeks supports statin myopathy (immune-mediated form will not improve)
Corticosteroid trial: Improvement supports inflammatory myopathy (except inclusion body myositis, which typically does not respond)
Intravenous immunoglobulin (IVIG): Improvement supports CIDP, multifocal motor neuropathy, or certain inflammatory conditions

Stepwise Investigation Algorithm

Approach Based on Clinical Localization:

All patients: CBC, CMP (including potassium, calcium, magnesium), CK, TSH, B12, glucose/HbA1c, ESR/CRP
If upper motor neuron pattern: MRI brain and/or spine (depending on localization)
If lower motor neuron pattern: EMG/NCS first; MRI spine if radiculopathy suspected
If neuromuscular junction suspected: Antibody testing (AChR, MuSK, VGCC), repetitive nerve stimulation, CT chest
If myopathy suspected: CK, EMG, myositis-specific antibodies, MRI muscle; proceed to muscle biopsy if diagnosis unclear
If no diagnosis after initial workup: Consider lumbar puncture, genetic testing, or referral to neuromuscular specialist

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Respiratory muscle weakness — dyspnea at rest, paradoxical breathing, unable to count to 10, FVC less than 20 mL/kg	EMERGENT	ICU admission, prepare for intubation, serial FVC monitoring every 2-4 hours
Acute hemiparesis with facial droop — sudden onset, within thrombolysis window	EMERGENT	Activate stroke code, emergent CT head, consider thrombolysis or thrombectomy
Spinal cord compression — weakness below a level, sensory level, bladder dysfunction, back pain	EMERGENT	Emergent MRI spine, IV dexamethasone if malignancy suspected, neurosurgical consultation
Rapidly ascending weakness — weakness progressing over hours to days, areflexia	EMERGENT	Admit to ICU or monitored setting, serial FVC, lumbar puncture, prepare for IVIG or plasmapheresis
Bulbar weakness with aspiration risk — severe dysphagia, pooling secretions, weak cough	URGENT	NPO status, speech therapy evaluation, consider NG tube, assess for myasthenic crisis
Rhabdomyolysis — dark urine, muscle pain, CK greater than 10,000 U/L	URGENT	Aggressive IV fluid resuscitation, monitor renal function and potassium, identify cause
New weakness in patient on immune checkpoint inhibitor	URGENT	Check CK, troponin (myocarditis risk), hold checkpoint inhibitor, consider steroids
Subacute progressive proximal weakness — over weeks, elevated CK	ROUTINE	Outpatient workup with EMG, myositis antibodies, consider muscle biopsy
Chronic slowly progressive weakness — months to years, stable	ROUTINE	Outpatient neurology referral, EMG/NCS, targeted testing based on pattern

Step 2: Localize the Lesion

The Most Critical Step: Before ordering tests or generating a differential, determine WHERE the problem is:

Clinical Features	Localization	Proceed To
Hyperreflexia, spasticity, Babinski positive, no atrophy, weakness in pyramidal pattern	Upper Motor Neuron	Algorithm A — Brain and Spinal Cord
Hyporeflexia or areflexia, flaccidity, atrophy, fasciculations, dermatomal or nerve distribution	Lower Motor Neuron	Algorithm B — Anterior Horn Cell and Peripheral Nerve
Fatigable weakness, normal reflexes, no sensory loss, ptosis and diplopia	Neuromuscular Junction	Algorithm C — NMJ Disorders
Proximal greater than distal weakness, normal or reduced reflexes, no sensory loss, elevated CK	Muscle	Algorithm D — Myopathy
Mixed UMN and LMN signs, fasciculations, no sensory loss, progressive	Motor Neuron Disease	Algorithm E — ALS Evaluation

Step 3: Follow the Appropriate Algorithm

Algorithm A: Upper Motor Neuron Weakness

Clinical Scenario	Most Likely Diagnosis	Action
Sudden onset hemiparesis, within 24 hours	Stroke (ischemic or hemorrhagic)	Emergent CT head → if ischemic and within window, thrombolysis/thrombectomy evaluation
Weakness below a level with sensory level, back pain	Spinal cord compression or myelopathy	Emergent MRI spine → neurosurgical consultation if compression
Relapsing-remitting symptoms, young patient, multiple lesions	Multiple sclerosis	MRI brain and spine with contrast → lumbar puncture for oligoclonal bands
Progressive spastic paraparesis, family history	Hereditary spastic paraplegia	MRI spine (to exclude structural cause) → genetic testing

Algorithm B: Lower Motor Neuron Weakness

Clinical Scenario	Most Likely Diagnosis	Action
Ascending weakness over days, areflexia, recent infection	Guillain-Barré syndrome	ICU admission → LP (elevated protein) → EMG/NCS → IVIG or plasmapheresis
Dermatomal weakness with radicular pain	Radiculopathy	MRI of relevant spine level → conservative management or surgical referral
Distal symmetric weakness with sensory loss (glove-and-stocking)	Peripheral polyneuropathy	EMG/NCS → glucose, B12, TSH, SPEP → treat underlying cause
Progressive proximal and distal weakness over months, areflexia	CIDP	EMG/NCS (demyelinating pattern) → LP → trial of IVIG or steroids
Asymmetric weakness, multifocal, pure motor	Multifocal motor neuropathy	EMG (conduction block) → anti-GM1 antibodies → IVIG trial

Algorithm C: Neuromuscular Junction Disorders

Clinical Scenario	Most Likely Diagnosis	Action
Fatigable ptosis and diplopia, worse later in day, bulbar symptoms	Myasthenia gravis	AChR antibodies → if negative, MuSK antibodies → CT chest for thymoma → pyridostigmine trial
Proximal weakness improving with activity, dry mouth, smoker	Lambert-Eaton myasthenic syndrome	VGCC antibodies → EMG with repetitive stimulation → CT chest for small cell lung cancer
Descending paralysis, diplopia, dilated pupils, recent food ingestion or wound	Botulism	Stool and serum botulinum toxin assay → antitoxin → supportive care in ICU
Known MG with acute worsening, respiratory distress	Myasthenic crisis	ICU → hold anticholinesterases initially → IVIG or plasmapheresis → identify trigger

Algorithm D: Myopathy

Clinical Scenario	Most Likely Diagnosis	Action
Proximal weakness, elevated CK, heliotrope rash or Gottron papules	Dermatomyositis	Myositis antibodies → EMG → MRI → muscle biopsy → malignancy screening
Proximal weakness, elevated CK, no rash	Polymyositis or immune-mediated necrotizing myopathy	Myositis antibodies (including anti-HMGCR, anti-SRP) → EMG → muscle biopsy
Proximal weakness in patient on statin	Statin myopathy	Stop statin → recheck CK in 4-6 weeks → if persistent, check anti-HMGCR antibodies
Proximal weakness in patient on chronic steroids	Steroid myopathy	CK usually normal → EMG may be normal → reduce steroid dose if possible
Asymmetric weakness, older patient, finger flexors and quadriceps weak	Inclusion body myositis	CK mildly elevated → EMG → muscle biopsy (rimmed vacuoles) → immunotherapy rarely helps
Exercise intolerance, “second wind” phenomenon, myoglobinuria	Metabolic myopathy (McArdle disease)	Forearm exercise test → genetic testing → muscle biopsy if needed

Algorithm E: Suspected Motor Neuron Disease

Clinical Scenario	Diagnosis	Action
Progressive weakness with mixed UMN and LMN signs in multiple regions, fasciculations, no sensory loss	Amyotrophic lateral sclerosis (ALS)	EMG (widespread denervation in 3+ regions) → MRI (exclude structural mimics) → genetic testing if familial → multidisciplinary care
Pure LMN syndrome, slowly progressive	Progressive muscular atrophy (LMN-predominant ALS variant)	EMG → exclude other LMN diseases → follow for UMN signs
Pure UMN syndrome, slowly progressive	Primary lateral sclerosis	MRI spine → EMG (to exclude LMN involvement) → follow for years before confirming diagnosis

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient cannot count to 20 in one breath	Measure FVC immediately; call ICU if FVC less than 20 mL/kg	Serial FVC monitoring every 2-4 hours; prepare for intubation
Weakness is rapidly progressing (hours)	Admit to monitored setting; check potassium; assess respiratory function	Lumbar puncture; EMG if available; consider IVIG empirically if GBS suspected
Patient has weakness and back pain	Check for sensory level; assess bladder function	Emergent MRI spine if any concern for cord compression
Known myasthenia gravis patient becomes weak	Assess respiratory function; differentiate crisis from cholinergic excess	ICU if respiratory compromise; hold pyridostigmine; start IVIG or plasmapheresis
CK is greater than 10,000 U/L	Aggressive IV fluids; check renal function and potassium	Monitor urine output; identify and treat underlying cause
Patient is on statin and develops weakness	Check CK; stop statin	Reassess in 4-6 weeks; if not improving, check anti-HMGCR antibodies
EMG shows widespread denervation with mixed UMN and LMN signs	Consider ALS; obtain MRI to exclude structural mimics	Refer to ALS clinic; discuss diagnosis sensitively; multidisciplinary planning
Inflammatory myopathy suspected	Check myositis-specific antibodies; consider malignancy screening	Muscle biopsy for confirmation; initiate immunosuppression with steroids
Weakness not improving despite treatment	Reassess diagnosis; consider alternative etiologies	Repeat EMG; consider muscle biopsy; check for overlapping conditions

Troubleshooting Refractory Weakness

Ask These Questions When Weakness Is Not Improving

Is the diagnosis correct? — Consider repeating EMG, muscle biopsy, or antibody testing
Are there multiple overlapping conditions? — For example, statin myopathy plus inflammatory myopathy; myasthenia plus thyroid disease
Is the treatment adequate? — Dose, duration, and adherence to therapy
Is there an occult malignancy? — Paraneoplastic syndromes may not respond until cancer is treated
Is there ongoing exposure? — Continued medication, toxin, or alcohol use
Has the condition evolved? — Some conditions (like inclusion body myositis) are inherently treatment-resistant
Is deconditioning contributing? — Physical therapy and rehabilitation may be needed alongside medical treatment

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

Localize before you diagnose: The single most important step in evaluating weakness is determining WHERE the lesion is (upper motor neuron, lower motor neuron, neuromuscular junction, or muscle). This dramatically narrows the differential and guides testing.

Mixed UMN and LMN signs = ALS until proven otherwise: The combination of hyperreflexia and spasticity (UMN) with fasciculations and atrophy (LMN) in the same patient is virtually pathognomonic for amyotrophic lateral sclerosis.

Respiratory failure is the killer in neuromuscular disease: Always assess respiratory function in acute weakness. The “20/30/40 rule” for Guillain-Barré syndrome: FVC less than 20 mL/kg, NIF less than -30 cm H₂O, or MEP less than 40 cm H₂O — consider intubation.

Fatigable weakness = neuromuscular junction: If weakness worsens with repeated activity and improves with rest, think myasthenia gravis. The ice pack test (improvement of ptosis after 2 minutes of ice) is a simple bedside diagnostic tool.

Normal CK does not exclude myopathy: Steroid myopathy, some endocrine myopathies, and late-stage dystrophies may have normal CK levels. Conversely, CK can be mildly elevated after exercise or EMG.

Sensory findings exclude pure motor conditions: Motor neuron disease, myopathy, and neuromuscular junction disorders do NOT cause sensory loss. If sensory symptoms are present, think neuropathy, radiculopathy, or central nervous system lesion.

Check the medication list: Statins are one of the most common causes of myopathy. Always ask about all medications, including over-the-counter supplements and recent changes in dose.

Lambert-Eaton = search for cancer: Up to 60% of Lambert-Eaton myasthenic syndrome cases are associated with small cell lung cancer. CT chest is mandatory, and surveillance may be needed for years.

Critical Pitfalls to Avoid

Missing respiratory compromise: Patients with neuromuscular respiratory weakness may not appear distressed until they are near respiratory failure. Measure FVC and NIF — do not rely on oxygen saturation or appearance alone.

Confusing fatigue with weakness: “Fatigue” is feeling tired; “weakness” is reduced muscle strength on examination. Many patients use these terms interchangeably. Always test actual muscle power.

Dismissing normal examination: Many serious conditions (early myasthenia gravis, early ALS, periodic paralysis between attacks) may have normal or near-normal examination. Trust the history if concerning.

Stopping statin too briefly: Toxic statin myopathy may take weeks to months to resolve. Do not conclude that statin was not the cause after only a few days. However, immune-mediated statin myopathy (anti-HMGCR) will NOT resolve with statin discontinuation alone.

Forgetting to ask about family history: Many neuromuscular diseases are hereditary (muscular dystrophies, hereditary neuropathies, periodic paralysis). Ask specifically about relatives with gait problems, wheelchair use, or early death.

Missing spinal cord compression: Back pain with weakness below a level is a surgical emergency. Delays in diagnosis lead to permanent paralysis. When in doubt, get emergent MRI.

Ordering the wrong test first: EMG before clinical localization wastes time and money. CK before clinical assessment may be misleading. Let the examination guide the investigations.

Assuming negative antibody test excludes myasthenia: Up to 15% of generalized myasthenia and 50% of ocular myasthenia are seronegative. If clinical suspicion is high, proceed with repetitive nerve stimulation and single-fiber EMG.

Key Takeaways

True weakness (reduced muscle power on examination) must be distinguished from perceived weakness (fatigue, asthenia) — they have entirely different differential diagnoses.
Anatomical localization is the foundation of neuromuscular diagnosis. Determine if the lesion is in the upper motor neuron, lower motor neuron, neuromuscular junction, or muscle before ordering tests.
Upper motor neuron signs (hyperreflexia, spasticity, Babinski) indicate brain or spinal cord pathology. Lower motor neuron signs (hyporeflexia, atrophy, fasciculations) indicate anterior horn cell, nerve root, or peripheral nerve pathology.
Acute ascending weakness with areflexia after a viral infection is Guillain-Barré syndrome until proven otherwise — monitor respiratory function closely and prepare for immunotherapy.
Respiratory failure is the most dangerous complication of acute neuromuscular weakness. Serial bedside assessments (single breath count, FVC) are more important than oxygen saturation.
Fatigable weakness (worsening with use, improving with rest) points to the neuromuscular junction — think myasthenia gravis or Lambert-Eaton syndrome.
Proximal weakness with elevated CK and skin rash is dermatomyositis — always screen for underlying malignancy.
Drug-induced myopathy is common and treatable. Statins, corticosteroids, and immune checkpoint inhibitors are frequent culprits. Always review the medication list.
Mixed upper and lower motor neuron signs without sensory loss is the hallmark of amyotrophic lateral sclerosis — a devastating diagnosis requiring sensitive communication and multidisciplinary care.
When in doubt about spinal cord compression, get an emergent MRI. The window for surgical intervention is narrow, and delays cause irreversible harm.

Quick Reference Algorithm

Systematic Approach to Muscle Weakness:

Confirm true weakness: Test muscle power on examination — distinguish from fatigue or pain-limited effort
Assess urgency: Check respiratory function, identify red flags (acute onset, ascending pattern, bulbar symptoms, sensory level)
Localize the lesion: Upper motor neuron, lower motor neuron, neuromuscular junction, or muscle — based on reflex pattern, tone, atrophy, sensory findings
Characterize the pattern: Proximal versus distal, symmetric versus asymmetric, acute versus chronic
Order targeted investigations: Baseline labs (CK, TSH, B12, electrolytes) for all; imaging and EMG based on localization
Generate differential diagnosis: Based on localization and pattern — prioritize common and treatable causes
Initiate treatment: Emergent intervention for life-threatening conditions; supportive care while establishing diagnosis
Arrange follow-up: Neurology referral for complex cases; monitor for progression and treatment response